LONG-TERM FOLLOW-UP OF PRIMARY GASTRIC DIFFUSE LARGE B-CELL LYMPHOMATREATED WITH MNHL-BFM-90
(Abstract release date: 05/19/16)
EHA Library. Zvonkov E. 06/09/16; 132531; E982
Dr. Eugeni Zvonkov
Contributions
Contributions
Abstract
Abstract: E982
Type: Eposter Presentation
Background
R-CHOP chemotherapy can induce favorable result for localized-stage primary gastric diffuse large B-cell lymphoma (PG-DLBCL) patients. But the presence of adverse factors (AF) and advanced stage decrease the efficacy of this therapy: 3-year progression-free survival (PFS) and overall survival (OS) are 43% and 64% respectively. The optimal treatment strategy for this pts still remains unknown.
Aims
Efficacy and safety assessment of the modified chemotherapy protocol NHL-BFM-90 (m NHL-BFM-90) in the treatment of the PG-DLBCL with AF.
Methods
Forty previously untreated pts with PG-DLBCL underwent m NHL-BFM-90 treatment between January 2004 and December 2015; mean age 47 years (range 37-72); age ≥60 years 9 pts (22,5%); M\F=23\17; stage >I 27 pts (68%); all pts had one or more AF. None of the patients received surgical treatment before chemotherapy and no consolidation radiotherapy. NHL-BFM-90 program (2 courses A and 2 courses B) was modified for PG-DLBCL in the following way: doxorubicin (50mg\m2) was added on the third day of course A. Twenty one (52%) pts received rituximab on day 0 prior to each course of therapy.
Results
The overall response rate (ORR) was 100%. Complete remission was achieved in 38 (95%) pts. From 2 pts with partial remission one died from progression of disease, one received salvage therapy. With a median follow-up of 74 months (range 3-146) disease-free and overall survival of 40 pts constituted 87,5% and 92,5%, respectively. All but one treatment failure belonged to the group without rituximab. Hematologic toxicity of grade 3 and 4 was observed in 80% of pts. Severe complications became the reason for subsequent switch to CHOP therapy after 2 courses in 6 cases. There was no treatment-related mortality.
Conclusion
The mNHL-BFM-90 demonstrated acceptable toxicity and high efficacy in patients with PG-DLBCL with AF.
Session topic: E-poster
Type: Eposter Presentation
Background
R-CHOP chemotherapy can induce favorable result for localized-stage primary gastric diffuse large B-cell lymphoma (PG-DLBCL) patients. But the presence of adverse factors (AF) and advanced stage decrease the efficacy of this therapy: 3-year progression-free survival (PFS) and overall survival (OS) are 43% and 64% respectively. The optimal treatment strategy for this pts still remains unknown.
Aims
Efficacy and safety assessment of the modified chemotherapy protocol NHL-BFM-90 (m NHL-BFM-90) in the treatment of the PG-DLBCL with AF.
Methods
Forty previously untreated pts with PG-DLBCL underwent m NHL-BFM-90 treatment between January 2004 and December 2015; mean age 47 years (range 37-72); age ≥60 years 9 pts (22,5%); M\F=23\17; stage >I 27 pts (68%); all pts had one or more AF. None of the patients received surgical treatment before chemotherapy and no consolidation radiotherapy. NHL-BFM-90 program (2 courses A and 2 courses B) was modified for PG-DLBCL in the following way: doxorubicin (50mg\m2) was added on the third day of course A. Twenty one (52%) pts received rituximab on day 0 prior to each course of therapy.
Results
The overall response rate (ORR) was 100%. Complete remission was achieved in 38 (95%) pts. From 2 pts with partial remission one died from progression of disease, one received salvage therapy. With a median follow-up of 74 months (range 3-146) disease-free and overall survival of 40 pts constituted 87,5% and 92,5%, respectively. All but one treatment failure belonged to the group without rituximab. Hematologic toxicity of grade 3 and 4 was observed in 80% of pts. Severe complications became the reason for subsequent switch to CHOP therapy after 2 courses in 6 cases. There was no treatment-related mortality.
Conclusion
The mNHL-BFM-90 demonstrated acceptable toxicity and high efficacy in patients with PG-DLBCL with AF.
Session topic: E-poster
Abstract: E982
Type: Eposter Presentation
Background
R-CHOP chemotherapy can induce favorable result for localized-stage primary gastric diffuse large B-cell lymphoma (PG-DLBCL) patients. But the presence of adverse factors (AF) and advanced stage decrease the efficacy of this therapy: 3-year progression-free survival (PFS) and overall survival (OS) are 43% and 64% respectively. The optimal treatment strategy for this pts still remains unknown.
Aims
Efficacy and safety assessment of the modified chemotherapy protocol NHL-BFM-90 (m NHL-BFM-90) in the treatment of the PG-DLBCL with AF.
Methods
Forty previously untreated pts with PG-DLBCL underwent m NHL-BFM-90 treatment between January 2004 and December 2015; mean age 47 years (range 37-72); age ≥60 years 9 pts (22,5%); M\F=23\17; stage >I 27 pts (68%); all pts had one or more AF. None of the patients received surgical treatment before chemotherapy and no consolidation radiotherapy. NHL-BFM-90 program (2 courses A and 2 courses B) was modified for PG-DLBCL in the following way: doxorubicin (50mg\m2) was added on the third day of course A. Twenty one (52%) pts received rituximab on day 0 prior to each course of therapy.
Results
The overall response rate (ORR) was 100%. Complete remission was achieved in 38 (95%) pts. From 2 pts with partial remission one died from progression of disease, one received salvage therapy. With a median follow-up of 74 months (range 3-146) disease-free and overall survival of 40 pts constituted 87,5% and 92,5%, respectively. All but one treatment failure belonged to the group without rituximab. Hematologic toxicity of grade 3 and 4 was observed in 80% of pts. Severe complications became the reason for subsequent switch to CHOP therapy after 2 courses in 6 cases. There was no treatment-related mortality.
Conclusion
The mNHL-BFM-90 demonstrated acceptable toxicity and high efficacy in patients with PG-DLBCL with AF.
Session topic: E-poster
Type: Eposter Presentation
Background
R-CHOP chemotherapy can induce favorable result for localized-stage primary gastric diffuse large B-cell lymphoma (PG-DLBCL) patients. But the presence of adverse factors (AF) and advanced stage decrease the efficacy of this therapy: 3-year progression-free survival (PFS) and overall survival (OS) are 43% and 64% respectively. The optimal treatment strategy for this pts still remains unknown.
Aims
Efficacy and safety assessment of the modified chemotherapy protocol NHL-BFM-90 (m NHL-BFM-90) in the treatment of the PG-DLBCL with AF.
Methods
Forty previously untreated pts with PG-DLBCL underwent m NHL-BFM-90 treatment between January 2004 and December 2015; mean age 47 years (range 37-72); age ≥60 years 9 pts (22,5%); M\F=23\17; stage >I 27 pts (68%); all pts had one or more AF. None of the patients received surgical treatment before chemotherapy and no consolidation radiotherapy. NHL-BFM-90 program (2 courses A and 2 courses B) was modified for PG-DLBCL in the following way: doxorubicin (50mg\m2) was added on the third day of course A. Twenty one (52%) pts received rituximab on day 0 prior to each course of therapy.
Results
The overall response rate (ORR) was 100%. Complete remission was achieved in 38 (95%) pts. From 2 pts with partial remission one died from progression of disease, one received salvage therapy. With a median follow-up of 74 months (range 3-146) disease-free and overall survival of 40 pts constituted 87,5% and 92,5%, respectively. All but one treatment failure belonged to the group without rituximab. Hematologic toxicity of grade 3 and 4 was observed in 80% of pts. Severe complications became the reason for subsequent switch to CHOP therapy after 2 courses in 6 cases. There was no treatment-related mortality.
Conclusion
The mNHL-BFM-90 demonstrated acceptable toxicity and high efficacy in patients with PG-DLBCL with AF.
Session topic: E-poster
{{ help_message }}
{{filter}}